• Our Science
• LTIB Website
• Home
• Links
• Organization
• Contact Info
• Positions
• Laboratory Chief
• Jeffrey Schlom
• Deputy Laboratory Chief
• James L. Gulley
• Investigators
• James W. Hodge
• Claudia M. Palena
• Assistant Clinical Investigator
• Ravi A. Madan
• Senior Associate Scientists
• Kwong Yok Tsang
• Staff Clinicians
• Christopher R. Heery
• Staff Scientists
• John W. Greiner

Our Science – LTIB Website

Laboratory of Tumor Immunology and Biology

Selected Links

• Postdoctoral Fellow Positions - The CCR environment affords the opportunity for exciting collaborations with other scientists in laboratories within NCI as well as those in other Institutes. Currently, we are recruiting for 2 postdoctoral fellows: Molecular Biologist/Virologist Applicants should have an interest and/or experience in the design and generation of novel vectors and strategies for use in anti-cancer vaccine development. Cellular Immunologist This position will involve the design and develop recombinant vaccine strategies for the induction and elucidation of host immune responses to anti-cancer vaccines.

• CCR Frontiers in Science - The first issue of CCR's scientific newsletter, Frontiers in Science, published and featured Strategies to enhance the potency of cancer vaccines/Drs. James Hodge and Jeffrey Schlom

• Publications of the LTIB - Updated List of Publications of the Laboratory of Tumor Immunology and Biology

• NCI Clinical Trial: Solid Tumor - Phase I Trial of NHS-IL12 in Subjects With Metastatic Solid Tumors

• NCI Clinical Trial: Prostate Cancer - A Randomized Phase 2.5 Study of [153]Sm-EDTMP (Quadramet) With or Without a PSA TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer

• NCI Clinical Trial: Breast Cancer - A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Patients With Metastatic Breast Cancer

• NCI Clinical Trial: Prostate Cancer - A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer

• NCI Clinical Trial: Prostate Cancer - A Trial of PROSTVAC +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (Prospect)

• BN ImmunoTherapeutics, Inc. - BN ImmunoTherapeutics is a CRADA partner of the LTIB.

• EMD Serono / Merck - EMD Serono is a CRADA partner of the LTIB.

• GlobeImmune, Inc. - GlobeImmune is a CRADA partner of the LTIB.

This page was last updated on 11/8/2011.